PH26696A - The use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs - Google Patents
The use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs Download PDFInfo
- Publication number
- PH26696A PH26696A PH38951A PH38951A PH26696A PH 26696 A PH26696 A PH 26696A PH 38951 A PH38951 A PH 38951A PH 38951 A PH38951 A PH 38951A PH 26696 A PH26696 A PH 26696A
- Authority
- PH
- Philippines
- Prior art keywords
- dihydro
- alkyl
- dimethyl
- denotes
- benzolblpyran
- Prior art date
Links
- 230000000414 obstructive effect Effects 0.000 title claims description 10
- 210000004072 lung Anatomy 0.000 title claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 125000003118 aryl group Chemical group 0.000 abstract description 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 2
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000026723 Urinary tract disease Diseases 0.000 abstract 1
- 150000004880 oxines Chemical class 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 37
- 230000008018 melting Effects 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 8
- 230000008602 contraction Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 206010006482 Bronchospasm Diseases 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 208000018569 Respiratory Tract disease Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- -1 biphenylyl Chemical group 0.000 description 6
- 230000007885 bronchoconstriction Effects 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 150000003951 lactams Chemical class 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- WXLPKTIAUMCNDX-UHFFFAOYSA-N 2h-pyran-3-ol Chemical compound OC1=CC=COC1 WXLPKTIAUMCNDX-UHFFFAOYSA-N 0.000 description 2
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QNXINFIEJAOBTB-UHFFFAOYSA-N 6-(benzenesulfonyl)-2,2-dimethylchromene Chemical compound C1=C2C=CC(C)(C)OC2=CC=C1S(=O)(=O)C1=CC=CC=C1 QNXINFIEJAOBTB-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 206010038419 Renal colic Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000287181 Sturnus vulgaris Species 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000001562 benzopyrans Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 1
- CILPHQCEVYJUDN-UHFFFAOYSA-N 2-(5-methyl-2-propan-2-ylcyclohexyl)oxyacetic acid Chemical class CC(C)C1CCC(C)CC1OCC(O)=O CILPHQCEVYJUDN-UHFFFAOYSA-N 0.000 description 1
- RVSASAQBLQHNPL-UHFFFAOYSA-N 2-(benzenesulfonyl)phenol Chemical compound OC1=CC=CC=C1S(=O)(=O)C1=CC=CC=C1 RVSASAQBLQHNPL-UHFFFAOYSA-N 0.000 description 1
- VNMCKLVHDJADEB-OUAUKWLOSA-N 2-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxyacetyl chloride Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(Cl)=O VNMCKLVHDJADEB-OUAUKWLOSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NCSLJPOZCXXHKO-UHFFFAOYSA-N 2-sulfonylchromene Chemical compound C1=CC=C2OC(=S(=O)=O)C=CC2=C1 NCSLJPOZCXXHKO-UHFFFAOYSA-N 0.000 description 1
- MGSHXMOLUWTMGP-UHFFFAOYSA-N 3'-carboxy-alpha-chromanol Chemical compound C1=CC=C2C(O)CCOC2=C1 MGSHXMOLUWTMGP-UHFFFAOYSA-N 0.000 description 1
- HXMNXYQJZLNHKS-UHFFFAOYSA-N 3-bromo-7-methoxy-2,2-dimethyl-6-(4-methylphenyl)sulfonyl-3,4-dihydrochromen-4-ol Chemical compound COC1=CC=2OC(C)(C)C(Br)C(O)C=2C=C1S(=O)(=O)C1=CC=C(C)C=C1 HXMNXYQJZLNHKS-UHFFFAOYSA-N 0.000 description 1
- QSILYWCNPOLKPN-UHFFFAOYSA-N 3-chloro-3-methylbut-1-yne Chemical compound CC(C)(Cl)C#C QSILYWCNPOLKPN-UHFFFAOYSA-N 0.000 description 1
- HRDCVMSNCBAMAM-UHFFFAOYSA-N 3-prop-2-ynoxyprop-1-yne Chemical class C#CCOCC#C HRDCVMSNCBAMAM-UHFFFAOYSA-N 0.000 description 1
- NCQRXBYVTLCISA-UHFFFAOYSA-N 4-(2,2-dimethylchromen-6-yl)sulfonylbenzonitrile Chemical compound C1=C2C=CC(C)(C)OC2=CC=C1S(=O)(=O)C1=CC=C(C#N)C=C1 NCQRXBYVTLCISA-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- XFAWJCSYYPCVFK-UHFFFAOYSA-N 6-(4-chlorophenyl)sulfonyl-7-methoxy-2,2-dimethylchromene Chemical compound COC1=CC=2OC(C)(C)C=CC=2C=C1S(=O)(=O)C1=CC=C(Cl)C=C1 XFAWJCSYYPCVFK-UHFFFAOYSA-N 0.000 description 1
- CWJWJFYRKMIOIG-UHFFFAOYSA-N 6-(benzenesulfonyl)-7-methoxy-2,2-dimethyl-3h-chromen-4-one Chemical compound COC1=CC=2OC(C)(C)CC(=O)C=2C=C1S(=O)(=O)C1=CC=CC=C1 CWJWJFYRKMIOIG-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- WIBBULMBDBDLMY-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-6-(4-methylphenyl)sulfonyl-3,4-dihydrochromen-4-ol Chemical compound COC1=CC=2OC(C)(C)CC(O)C=2C=C1S(=O)(=O)C1=CC=C(C)C=C1 WIBBULMBDBDLMY-UHFFFAOYSA-N 0.000 description 1
- FVNAOSFNDOTNHC-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-6-(4-methylphenyl)sulfonyl-3h-chromen-4-one Chemical compound COC1=CC=2OC(C)(C)CC(=O)C=2C=C1S(=O)(=O)C1=CC=C(C)C=C1 FVNAOSFNDOTNHC-UHFFFAOYSA-N 0.000 description 1
- VOBXUMJEWPMGJW-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-6-(4-methylphenyl)sulfonylchromene Chemical compound COC1=CC=2OC(C)(C)C=CC=2C=C1S(=O)(=O)C1=CC=C(C)C=C1 VOBXUMJEWPMGJW-UHFFFAOYSA-N 0.000 description 1
- DISYDHABSCTQFK-UHFFFAOYSA-N 7-methoxy-2,3-dihydrochromen-4-one Chemical compound O=C1CCOC2=CC(OC)=CC=C21 DISYDHABSCTQFK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical class C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000008371 chromenes Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000138 effect on histamine Effects 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical class BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QYRFJLLXPINATB-UHFFFAOYSA-N hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride Chemical compound Cl.Cl.NC1=C(F)C(N)=C(F)C(F)=C1F QYRFJLLXPINATB-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000036972 phasic contraction Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical class ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Abstract
The use of 3,4-dihydro-2H-benzo[b]pyrans of the formula I <IMAGE> in which R<1> is H, OH, (C1-C2)-alkoxy, (C1-C2)-alkyl or NR<4>R<5>, where R<4> and R<5> are identical or different and are H, (C1-C2)-alkyl or (C1-C3)-alkylcarbonyl, R<2> and R<3> are identical or different and are alkyl with 1-4 C atoms, Ar is an aromatic or heteroaromatic system which is unsubstituted or substituted by 1 to 3 identical or different radicals (C1-C2)-alkyl, (C1-C2)-alkoxy, halogen, trifluoromethyl, CN, NO2, CO-(C1-C2)-alkyl or SOm-(C1-C2)-alkyl with m = 1 or 2, n is 1 or 2, X is a chain (CH2)r which can be interrupted by a heteroatom O, S or NR<6> where R<6> is H or (C1-C4)-alkyl and r is the numbers 2, 3, 4 or 5, for the production of a medicament for urinary tract disorders.
Description
. oh - 26696 - 1.-
HOECHST AKTIENGESELLSCHAFT HOE B88/F 177 Dr.v.F./AP
The use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs and/or disorders of the efferent urinary passages.
The invention relates to the use of 3,4-dihydro-2H-benzo- [blpyrans of the formula 1 " a ( 7 Coa? whol . . C=0 : - Ss. B { ) N - QS 5 - ho : .
Ar-50, ~_ 1 OH a e E30
Ol. 3d 2 | = £3 1 7 5 1 R i ’ 3 2 \
R ° R3 of® | g - . : hE . ’ 5 ! > - vl " which x & x 5
R' represents H, OH, (Cq-Cp)-alkoxy, (C4q-Cp)=alkyl LQ » or NRYR, where R* and RS are identical or different = ¥ and represent H, (C4-Cp)-alkyl or (C4-C3)-alkyl- carbonyl,
RZ and RS are identical or different and represent alkyl having 1-4 carbon atoms, a § 15 Ar represents an aromatic or heteroaromatic system which is unsubstituted or substituted by 1 to 3 identi-al or different radicals (C4q-Cp)-alkyl, (C4-Cp)-alkoxy, halogen, trifluoromethyl, CN, NOp, €CO-(Cq-Cp)-alkyl or
SO,-(Cq-C2)-alkyl with m = 1 or 2, n represents 1 or 2,
X represents a chain (CHp). which can be interrupted by a heteroatom 0, S or NRS, where RS denotes H or (C4-C4)-alkyl, and r represents the numbers 2, 3, 4 or 5,
CAD ORIGINAL 9 a 66 96 for the preparation of a remedy for obstructive func- tional disorders of the lungs and/or disorders of the efferent urinary passages.
An aromatic system Ar is preferably to be understood to be phenyl, naphthyl or biphenylyl, and a 5- or 6-membered heteroaromatic system Ar is preferably a radical of a 5- or 6-membered 0, N and/or S heterocyclic ring, especially furyl, thienyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl or triazinyl.
Halogen is to be understood to be F, CL, Br or I, prefer- “2 ably F and CL.
Carbon atoms 3 and 4 of the 3,4-dihydro-2H-benzolblpyran system (also called "chroman system’ hereinafter for brevity) of the formula I are asymmetrically substituted.
In this connection, the invention relates only to those compounds which have opposite configurations at these centers, that is to say have a "trans" orientation of the substituents on these carbon atoms. If one of the sub- stituents RY, ArsSOg,, RZ and/or R> contains centers of asymmetry, or if R® and R> are not the same (and thus generate an asymmetric carbon atom), the invention & relates to compounds with centers both of the § and of ~ the R configuration.
The compounds can be in the form of optical isomers, di- astereoisomers, racemates or mixtures thereof.
Preferably used are compounds of the formula I in which rR] to rR and ArS0, have the abovementioned meanings, but X represents a chain (CHP), with r = 3 or 4.
Very particularly preferably used are those compounds in which R to R> have the abovementioned meanings, Ar represents phenyl which is unsubstituted or substituted
- 3 = as defined above, n represents 2, and X represents a chain (CH) pr with r = 3 or 4.
Especially preferably used are those compounds in which rR denotes H, RZ and rR represent (Cq-Cy)-alkyl,
Ar represents phenyl which is unsubstituted or substituted once by (Cq-Cy)-alkyl, (C4-Cp)-alkoxy or halogen, n represents 2, and X represents a chain (CH), with r = 3 or 4.
Likewise preferred are compounds with rR! equal to H,
R® and R° equal to (Cq-Cp)-alkyl, X equal to (CHp)3,.
Ar equal to CgHuCL, and n equal to 2, as well as those
Co with rR equal to H, rR and RS equal to (Cq-Cp)-alkyl,
A Ar equal to phenyl, n equal to 2, and X equal to (CHp)s3.
EA EP 0,176,689 describes the use of benzopyrans for res- ‘ ‘piratory tract diseases and/or disorders of the gastro- oo intestinal tract and/or of the uterus, with special emphasis being placed on those disorders occurring in smooth muscular contractions. EP 207,614 describes the use of benzopyrans for incontinence. Furthermore, J.
Med. Chem. 1986, 29, 2194 - 2201 discloses that compounds of this type may have hypotensive properties. It has now been found, surprisingly, in pharmacological investiga- i tions that compounds 1 are likewise suitable for use as @ remedies for respiratory tract diseases and/or disorders of the efferent urinary passages.
Hence the invention relates to the use of the compounds of the formula I for the treatment and prophylaxis of the diseases detailed above; particutarly preferred in this connection are those diseases in which there is a dis- turbance of the smooth muscular contractions of the parti- cular organs, such as, for example, asthma, incontinence or renal colic. Particularly important in this connec- tion are those compounds 1 whose hypotensive properties are Less pronounced.
The invention is furthermore directed at a pharmaceutical product for the treatment of obstructive functional dis- orders of the tungs, which contains a compound 1 as active substance besides customary additives, as well as at a compound 1 for use for the treatment of obstructive functional disorders of the Lungs and/or of the efferent urinary passages.
Very particularly preferred js the use of 3,4-dihydro-2,2- dimethyl-6-(2-chlorophenylsulfonyl)-trans-4-(2-oxo-1- pyrrolidinyl)-2H-benzolblpyran-3-ol for the preparation of a remedy for disorders of the efferent urinary pass- ages and the use of 3,4-dihydro-2,2-dimethyl-6-phenyl- ) sulfonyl-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran- 3-ol for the preparation of a remedy for obstructive respiratory tract diseases.
The invention furthermore embraces the use of the com- oo "© pounds according to the invention for the preparation of pharmaceuticals which are used for the treatment and prophylaxis of the abovementioned diseases.
The compounds I can be prepared by the following pro- cesses: - by {) a) reacting compounds of the formula 11
OH 11
Yo Br
EOL
R3 1 0
R RZ in which rR to R3 and ArS0, are as defined above, with
Lactams of the formula Ill
X
( Xo 111
N lI
H b) reacting compounds of the formula 1V -50 ss r3 1 0
R RZ in which rR to R3 and ArsSO, are as defined above, with the Lactams of the formula III,
LC) ¢) acylating compounds of the formula V
NH;
ASO, OH 3 Vv) 1 R
R 07 Np2 in which R' to R> and ArsO, are as defined above, to give the compounds VI
BN Xs ee LL - VI
R3
Ny rR 7 0“ Ng? 0) ~ in which Y is a leaving group such as, for example, chlorine or bromine, and rR! to R® and ArSO, are as defined above, and cyclizing the Latter to give the compounds I, d) oxidizing compounds of the formula VII 2 . ( N~ Hy I’
V
ArsSO, OH 3 1 © Ey
R Rr?
in which rR to RS and ArS0, are as defined above, to give the compounds 1.
Where the compounds [I are prepared by methods a) or b), this is carried out by reacting the compounds II or IV in a suitable solvent, preferably in dipolar aprotic sol- vents such as, for example, dimethyl sulfoxide or THF, with the Lactams 111, preferably with the action of bases such as, for example, sodium hydride, potassium tert.- butylate or similar bases known to be suitable for lactam
N-alkylations. The temperature for this reaction can be varied within wide Limits; it is preferably carried out between 0° and room temperature or at temperatures
LJ which may be slightly above room temperature.
Lactams of the formula I11 are known in many cases, OF they can readily be prepared by methods known from the
Literature. Compounds 11 or IV are new. They can be prepared, for example, by the following synthetic route: i
Compounds of the formula VIII 0
Or L 3 VII rR” 0 02 ry
J) 20 in which RY, rR? and RS are as defined above, are reacted with acid chlorides Ar-S0n-CL in a type of Friedel-
Crafts acylation in a manner known per se to give com- pounds of the formula IX
Arso, %
IX
"TOL. L )
RZ in which RY, RZ, RS and Ar and n are as defined above.
The Latter are converted by reductions under standard conditions, for example by NaBH, in methanol, into the compounds X
OH
\ "OL 3 X 2 oR
R which are then subjected to elimination of water, for example by pyridine/phosphorus oxychloride, resulting in compounds of the formula XI: . AxSO, xn 0
LL ] R3
R RZ
Compounds XI can now easily be converted by standard methods into the epoxides 1V or the bromohydrins 11. 1f in this reaction sequence R means NHp or OH, protec~ tive groups may be necessary, suth as, for example, the dimethylaminomethylene group for NHp or the acetyl or ' methyl group for the OH group. These are eliminated again at suitable stages, preferably after the reactions . " described in process a) or b) have been carried out, by
LD) 15 co. 'entional methods.
Chromenes of the formula XI are, in some cases, prepared in a manner known per Sse by thermally induced cyclization of the corresponding propargyl ethers XII
ArsoO +B rR Ns r2 ®
These in turn can be prepared in a manner known per se from the phenols X111 and the propargyl chlorides XIV.
RZ
Arso, HC = C - c - Ql
Tel »
R' oH
X111 X1v
It is possible and particularly beneficial to use pro- cesses c¢) and d) when the final products 1 are desired as pure enantiomers. Compounds V and Vil are, in con- trast to compounds 1, basic and thus able to form salts with organic acids. 1t is possible, by crystallization with a suitable optically pure acid such as, for example,
CJ (+)-mandel ic acid or (+#)-lactic acid, in a manner known ) per se to obtain them as pure enantiomers, and convert them by processes ¢) and d) into final products 1 as pure enantiomers. ov However, ¥inal products 1 can also be obtained as ‘pure : enantiomers from racemic final products I by conventional methods of racemate resolution such as, for example, chromatographic separation using chiral phases, or derivatization of the racemic products with optically pure acid derivatives (ester formation via the 3-hydroxy group of the chroman system) or with optically pure iso- ~ cyanates (carbamate formation via the 3-hydroxy group). () 20 The diastereoisomeric isocyanates or esters obtained in this way can be separated by conventional methods (crystallization or chromatography) and converted into the optically pure final compounds I with elimination of the optically active auxiliary group on the 3-0H group.
Separation of the diastereomeric 3-menthoxyacetates has proven particularly advantageous in this connection.
As already mentioned, the compounds 1 can be used accord- ing to the invention as agents for the treatment of obstructive respiratory tract diseases and/or for the treatment of disorders of the efferent urinary passages.
In this connection, pharmaceuticals which contain the compounds I can be administered orally, parenterally, intravenously, rectally or by inhalation, with the pre- ferred administration form being dependent on the disease which is to be treated. In this connection, the com- pounds I can be used alone or together with pharmaceuti- cal auxiliaries, specifically both in veterinary and in human medicine.
The expert is famitiar, on the basis of his expert know- ledge, with the auxiliaries which are suitable for the desired pharmaceutical formulation. Besides solvents, \ gel-formers, suppository bases, tablet auxiliaries and 7 other active substance vehicles, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoam agents, flavorings, preservatives, solubilizers or pigments.
For a form for oral use, the active compounds are mixed with the additives suitable for this purpose, such as excipients, stabilizers or inert diluents, and converted by the customary methods into suitable administration forms such as tablets, coated tablets, hard gelatin cap- sules, aqueous, alcoholic or oily suspensions or aqueous, alcoholic or oily solutions. Examples of inert vehicles
CO) which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. This preparation can be carried out both as dry and as wet granules. Examples of suitable oily excipients or solvents are vegetable or animal oils, such as sunflower oil or fish Liver oil.
For subcutaneous or intravenous administration, the active compounds are converted, if desired with the sub- stances customary for this purpose, such as solubilizers, emulsifiers or other auxiliaries, into a solution, sus- pension or emulsion. Examples of suitable solvents are water, physiological saline or alcohols, for example ethanol, propanol or glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
Examples of pharmaceutical formulations suitable for administration in the form of aerosols or sprays are solutions, suspensions or emulsions of the active sub- stance of the formula I in a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents. The formulation can, if required, also contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers, as well
Co as a propellant gas. A formulation of this type normally
J contains the active substance in a concentration of about 0.1 to 10, in particular of about 0.3 to 3, % by weight.
The dosage of the active substance of the formula I which i. | is to be administered, and the frequency of administra- tion, depend on the strength of action and duration of action of the compound used, and, additionally, on the nature and severity of the disease which is to be treated, as well as on the sex, age, weight and individual res- ponse of the mammal which is to be treated. On average, the recommended daily dose of a compound of the formula 1 for a patient weighing about 75 kg is at least 0.1 mg, y preferably at least 1 mg, up “0 2 maximum of 100 mg, preferably up to a maximum of 10 mg. In this connection, several, for example up to 4, single doses a day may be necessary for acute episodes of the disease, for example for attacks of asthma or of renal colic, whereas one dose may also suffice for prophylaxis.
In this connection, the compounds I can be administered alone or in combination with other compounds, for example when used for obstructive respiratory tract disorders with Bp-agonists such as salbutamol, or with theo- phyltine or with disodium cromoglycate.
When used for disorders of the efferent urinary passages, examples of partners in the combination are those having antibacterial or analgesic activity.
The compounds of the formula I compiled in the table which follows are particularly well suited: 1) 2,2-dimethyl-3,4-dihydro-7-methoxy-6-(p-chlorophenyl- sulfonyl)-trans-4-(2-oxo-1-pyrrolidinyl})-2H-benzolbl- pyran-3-ot, 2) 2,2-dimethyl-3,4-dihydro-6-(p-chlorophenylsulfonyl)- , 10 trans~4-(2-oxo-1-piperidinyl)-2H-benzolblpyran-3-ol, ~~.’ 3) 2,2-dimethyl-3,4-dihydro-6-(p-nitrophenylsulfonyl)- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ot, 4) 2,2-dimethyl-3,4~dihydro-6-(p-cyanophenylsulfonyl)- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 5) 2,2-dimethyl-3,4-dihydro-6-(p-methoxyphenylsulfonyl)- trans-4-(2-oxo-1-pyrrotidinyl)-2H-benzolblpyran-3-ol, 6) 2,2-dimethytl-3,4-dihydro-6-(p-trifluoromethylphenyl- sulfonyl)-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolbl- 7) pyran-3-ol, . 7) 2,2-dimethyt-3,4-dihydro-6-(p-methylsulfonylphenyl- sulfonyl)-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolb]- pyran-3-ol, 8) 2,2-dimethyl-3,4-dihydro-6-(p-acetylphenylsulfonyl)- trans-4~-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 9) 2,2-dimethyl-3,4-dihydro-7-methylamino-6-phenylsulf- onyl-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzo{blpyran- 3-0l,
10) 2,2-dimethyl-3,4-dihydro-7-fluoro-6-phenylsulfonyl- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 11) 2,2-diethyl-3,4-dihydro-7-fluoro-6-phenylsulfonyl- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 12) 2 ,2-dimethyl-7-chloro-3,4-dihydro-6-phenylsulfonyl~- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 13) 2,2-dimethyt-3,4-dihydro-6-(4-chloro-3-methylphenyl- sulfonyl)-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolbl- pyran-3-ol, () 10 14) 2,2-dimethyl-3,4-dihydro-6-(4-chlorophenylsulfonyl)- trans-4-(5-oxo-3-thiazolidinyl)-2H-benzolblpyran-3-ol, 15) 2,2-dimethyl-3,4-dihydro-trans-4-(4-methyl-2-oxo-1- . piperazinyl)-6-phenylsul fonyl-2H-benzolblpyran-3-ol, 16) 2,2-dimethyl-3,4-dihydro-6-phenylsulfonyl-trans-4- (2-ox0-1-morpholinyl)-2H-benzolblpyran-3-ol, 17) 2,2-dimethyl-3,4-dihydro-6-phenylsul fonyl-trans-4- (5-oxo-3-oxazolinyl)-2H-benzolblpyran-3-ol, (7) 18) 3,4-dihydro-2,2-dimethyl-6-(p-fluorophenyl-ulfonyl)- - trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 19) 3,4-dihydro-2,2-dimethyl-6-(o-fluorophenylsulfonyl)- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 20) 3,4-dihydro-2,2-dimethyl-6-(3-pyridylsulfonyl)-trans- 4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol, 21) 3,4-dihydro-2,2-dimethyl-6-(2-pyrimidinylsulfonyl)~ trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-otl, 22) 3,4-dihydro-2,2-dimethyt-6-(2-furylsulfonyl)-trans-
4~(2~oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol.
Example 1 3,4-Dihydro-2,2-dimethyl-7-methoxy-6-(p-tolytsulfonyl)- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzol(blpyran-3-ot 4.3 g (0.0097 mole) of 3-bromo-3,4-dihydro-2,2-dimethyl- 7-methoxy-6-(p-tolylsulfonyl)-2H-benzo[b]pyran-4-ol are dissolved in 28 ml of dimethyl sulfoxide, and 3.5 ml of 2-pyrrolidinone (0.0465 mole) and 0.78 g of sodium hydride (80% suspension in oil) (0.0325 mole) are added, - 10 and the mixture is stirred at 40°C for 3 hours. It is (2 Left to stand overnight and then poured onto ice-water and filtered with suction. The precipitate is recrystal- oo . Llized from isopropanol. White crystals of melting point: 263 - 65°C. . 15 Preparation of the starting compound: oo So 3-Bromo-3,4-dihydro-2,2-dimethyl-7-methoxy-6-(p-tolyl- sul fonyt)-2H-benzolblpyran-4-ol is obtained from 2,2- dimethyl-7-methoxy-6-(p-tolylsulfonyl)-2H-chromene and
N-bromosuccinimide in a 9:1 mixture of dimethyl sulf- oxide and H,0. Melting point: 200-201°¢C i) 2,2-Dimethyl-7-methoxy-6-(p-tolylsulfonyl)-2H~chromene is obtained from 2,2~-dimethyl-7-methoxy-6-(p-tolylsulf- onyl)chroman-4-ol with phosphorus oxychloride/pyridine in benzene. Melting point: 132 - 33% 2,2-Dimethyl-7-methoxy-6-(p-tolylsulfonyl)chroman-4-ol is obtained from 2,2-dimethyl-7-methoxy-6-(p-tolylsulf- onyl)chroman-4-one with NaBH; in ethanol.
Melting point: 196 - 97% 2,2-Dimethyl-7-methoxy-6-(p-tolylsulfonyl)chroman-4-one is obtained from 2,2-dimethyl~7-methoxychroman-4-one and p-toluenesul fonyl chloride in the presence of aluminum chloride in methylene chloride.
Melting point: 221 - 23°C.
Example 2 3 4-Dihydro-2,2-dimethyl-7-methoxy=6-(p-tolylsulfonyl)= trans-4-(2-oxo-1-piperidinyl)-2H-benzolblpyran-3-ol 5 g (0.011 mole) of 3-bromo-3,4-dihydro-2,2-dimethyl-7- methoxy-6-(p-tolylsulfonyl)-2H-benzolblpyran-4-ol are dissolved in 32 mL of dimethyl sulfoxide, and 4.9 g of valerolactam (0.0526 mole) and 0.8 g (0.033 mote) of NaH,
JE 10 80% suspension in oil, are added, and the mixture is \ stirred at 40°c for 5 hours. It is poured into ice- water and filtered with suction. The residue is extrac- +. ‘ted by boiling several times with methanol. . White crystals of melting point: 261 - 63°C ’ 15 Example 3 . Ce So Co 3 4-Dihydro-2,2-dimethyl-7-methoxy-6-phenylsulfonyl= trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol
The compound is prepared in analogy to Example 1 from 3- bromo-3,4-dihydro-2,2-dimethyl-7-methoxy-6-phenylsulfon-
CO) 20 yl-2H-benzolblpyran-4-ol. . white crystals of melting point: 227 - 29°%¢
Separation of the ant ipodes, Example 3a 1.075 g (0.0025 mole) of (+)-3,4-dihydro-2,2-dimethyl-7- methoxy-6-phenylsulfonyl-trans-4-(2-oxo-1-pyrrolidinyl)= 2H-benzolblpyran-3-ol are dissolved in 5 mL of 1,2-di- chlorobenzene, and 0.9 g¢ of S(-)-1-phenyltethyl isocyanate is added, and the mixture is stirred at 140°C for about 12 h. The complete mixture is subsequently chromato- graphed on silica gel with the solvent system toluene/ ethyl acetate 1:1. The diastereomeric carbamate which migrates slower can be enriched and obtained pure by crystallization from toluene (melting point 243-245°C).
Hydrolysis with NaOH in EtOH at 80°C results in (+)- 3,4-dihydro-2,2-dimethyl~-7-methoxy-6-phenylsulfonyl- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol of /‘ melting point: 209-211°C and [aly = + 109° (c¢ = 0.28;
CHCL3)
Preparation of the starting material: 3-8Bromo-3,4-dihydro-2,2-dimethyl-7-methoxy-6-phenyl - sulfonyl-2H-benzolblpyran-4-ol is obtained from 2,2- -. dimethyl-7-methoxy-é-phenylsul fonyl-2H-chromene and N- () bromosuccinimide in a 9:1 mixture of dimethyl sulfoxide and Hp0. Melting point: 202 - 203°c. 2,2-Dimethyl-7-methoxy-é-phenylsul fonyl-2H-chromene is obtained from 2,2-dimethyl~-4-hydroxy-7-methoxy-6é-phenyl- . sulfonylchromene with pyridine/phosphorus oxychloride in benzene. Melting point: 140 - 41°C. oo 2,2-Dimethyl-4~-hydroxy-7-methoxy-6-phenylsulfonylchroman is obtained from 2,2-dimethyl-7-methoxy-6-phenylsulfonyl- ' 20 chroman-4-one with sodium borohydride in methanol.
Melting point: 146 - 147°C. ( : 2,2-Dimethyl-7-methoxy-6-phenylsulfonylchroman-4-one is obtained from phenylsulfonyl chloride, 2,2-dimethyl-7~- methoxychroman-4-one and aluminum chloride in methylene chloride.
Melting point: 223 - 25°C
Example 4 3,4-Dihydro-2,2-dimethyl-6-(4-methylphenylsulfonyl)- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol 0.75 g (0.025 mole) of 80% NaH is introduced into 8.2 g
(0.02 mole) of I-bromo-3,4-dihydro-2,2-dimethyl-6-(4- methylphenylsulfonyl)-2H-benzolblpyran-4-ol in 30 mL of dimethyl sulfoxide. After stirring at 20° for one hour, a further 0.75 g (0.025 mole) of 80% NaH and 1.9 ml (0.025 mole) of 2-pyrrolidone are added, and the mixture is stirred at 40° for 45 minutes and at 20° for 6 hours.
It is introduced into ice-water and then the precipitate is filtered off with suction, dried and recrystallized from methanol several times.
Crystals of melting point: 242 - 243°C.
Preparation of the starting material { rn _ 3-Bromo-3,4-dihydro-2,2-dimethyl-6-(4-methylphenyl=- sulfonyl)-2H-benzolblpyran-4-ol 14.2 g (0.08 mole) of freshly recrystallized N-bromo-
B 15 succinimide are introduced into 12.6 g (0.04 mole) of oo | 5 2-dimethyl-6-(4-methylphenylsulfonyl)chromene ih a solution composed of 70 ml of dimethyl sulfoxide and 1.4 mL of water while cooling (isopropanol /dry ice) at about 15°C. The temperature rises transiently to 27°.
It is cooled to 20°c and, after stirring for one hour, introduced into ice/ethyl acetate. The ethyl acetate phase is washed several times with water and dried over yy Nap$04. The bromohydrin derivative crystallizes on : concentration. Crystals of melting point: 141 - 142%¢.
Example 5 3, 4-Dihydro-2,2-dimethyl-6-phenylsulfonyl-trans-4-(2-0x0= 1-pyrrolidinyl)-2H-benzolblpyran-3-ol
A solution of 6.3 g (0.02 mole) of 3,4-dihydro-2,2-di- methyl-3,4-epoxy-6-phenylsul fonyl-2H-benzolblpyran in 20 ml of DMSO is added dropwise, at 20°, to a suspension of 0.6 g (0.02 mole) of 80% NaH in 10 mL of DMSO. Then 2.3 mL (0.03 mole) of 2-pyrrolidinone are added, and the mixture is stirred at 45° for one hour. After it has stood at 20° overnight it is introduced into ice-water.
The precipitate is filtered off with suction, washed to neutrality, dried and chromatographed on silica gel with methylene chloride/methanol 19:1. 30 mL fractions are collected. Fractions 12-25 are concentrated, and the residue is recrystallized from acetonitrile.
Melting point: 201-202°
Preparation of the starting material: 3,4-Dihydro-2,2-dimethyl-3,4-epoxy-6-phenylsul fonyl-2H- benzol[blpyran is obtained from 3-bromo-3,4-dihydro-2,2- dimethyl-6-phenylsulfonyl-2H-benzolblpyran-4-ol with NaH in DMSO. a Melting point: 103-105° 3-Bromo-3,4-dihydro-2,2-dimethyl-6-phenylsulfonyl-2H- benzolblpyran-4-ol is obtained from 2,2-dimethyl-6- phenylsulfonyl-2H-chromene and N-bromosuccinimide in a 9:1 mixture of dimethyl sulfoxide and Hp0.
Melting point: 126° 2,2-Dimethyl-6-phenylsulfonyl-2H-chromene, with melting point 70-719, was prepared by known methods from 4 - phenylsulfonylphenyl 1,1-dimethylpropargyl ether. This ether is obtained, likewise in a known manner, from 4- ro phenylsul fonylphenol and 3-methyl-3-chlorobutyne. . (+)-3,4-Dihydro-2,2-dimethyl-6-phenylsulfonyl-4-(2-oxo- 1-pyrrolidinyl)-2H-benzolblpyran-3-ol (Example 5a) © (+)-3,4-Dihydro-2,2-dimethyl-6-phenylsulfonyl-4-(2-0oxo- 1-pyrrolidinyl)-2H-benzolblpyran-3-ol is esterified with (-)-menthoxyacetyl chloride by standard methods. The diastereomeric esters are separated on a silica gel column with methylene chloride/ethyl acetate (9:1) and hydrolyzed by stirring at 20° with alcoholic sodium ethylate solution. After dilution with cold water, the precipitate is filtered off with suction and washed to neutrality and triturated with ether. (+)-3,4-Dihydro-2,2-dimethyl-6-phenylsul fonyl-4-(2-0oxo- 1-pyrrolidinyl)-2H-benzolblpyran-3-ol
Melting point: 122-123° [alp = + 39.5% (¢ = 1, ethanol)
Example 6 6-(4-Chlorophenylsulfonyl)-3,4-dihydro-2,2-dimethyl-7- methoxy-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran- 3-ol
The compound is prepared in analogy to Example 1 from 3- bromo-6-(4-chlorophenylsul fonyl)-3,4-dihydro-2,2-dimethyl- . 7-methoxy-2H-benzolblpyran-é4-ol.
White crystals with melting point: 260-262°¢C
Preparation of the starting compounds: " In analogy to Example 1:
Co is 4-8roms-6-(h=chlorophenylsulforyl)=3,4-dihydrb=2,2- : dimethyl-7-methoxy-2H-benzolblpyran-4-ol with melting point: 175-177°¢C 6-(4-Chlorophenylsulfonyl)-2,2-dimethyl-7-methoxychromene with melting point: 142-143%C ’ 7) 20 Example 7 6-(4-Bromophenylsulfonyl)-3,4-dihydro-2,2-dimethyl-7- methoxy-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran- 3-0l
In analogy to Example 1 from 3-bromo-6-(4-bromophenyl- sulfonyl)-3,4-dihydro-2,2-dimethyl-7-methoxy-2H-benzolbJ- pyran-4-ol.
White crystals of melting point: 281-282°C.
Example 8 3,4-Dihydro-2,2-dimethyl-7-methoxy-6-(4-methoxyphenyl- sulfonyl)-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolbl-
pyran-3-ol
The compound is prepared in analogy to Example 1 from 3- bromo-3,4-dihydro-2,2-dimethyl-7-methoxy-6-(4-methoxy- phenylsul fonyl)-2H-benzolblpyran-4-ol and has a melting point of 286-287°C.
Example 9 3,4-Dihydro-2,2-dimethyl-7-methoxy-6-(2-thienylsulfonyl)- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol
In analogy to Exampte 1 from 3-bromo-3,4~-dihydro-2,2- dimethyl-7-methoxy-6-(2-thienylsulfonyl)-2H-benzolblpyran- { — 4-ol, melting point: 135-136°C.
Example 10 3,4-Dihydro-2,2-dimethyl-7-ethoxy-6-phenylsulfonyl-trans- 4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol
In analogy to Example 1 from 3-bromo-3,4-dihydro-2,2- dimethyl-7-ethoxy-6-phenylsulfonyl-2H-benzolblpyran-4-ol, melting point: 197-198%cC.
Example 11 3,4-Dihydro-2,2-dimethyl-7-methoxy-6-phenylsulfonyl- ro) 20 trans-4-(2-oxo-1-piperidinyl)-2H-benzolblpyran-3-ol
In analogy to Example 2 from 3-bromo-3,4-dihydro-2,2- dimethyl-7-methoxy-6-phenylsulfonyl-2H-benzolblpyran-4- ol. White crystals of melting point: 157-158%cC.
Example 12 6-(4-Cyanophenylsulfonyl)-3,4-dihydro-2,2-dimethyl- trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ot
In analogy to Example 1 from 3-bromo-6-(4-cyanophenyl- sulfonyl)-3,4-dihydro-2,2-dimethyl-2H-benzolblpyran-4-ol.
White crystals of melting point: 234-235%C.
so - 20 -
Preparation of the starting material: 3s_gromo-6-(4-cyanophenylsulfonyl)=-3,4-dihydro-2,2- dimethyl-2H-benzolblpyran-4-ol is obtained as described in Example 3 from 6-(4-cyanophenylsulfonyl)-2,2-dimethyl- 3-chromene.
Melting point: 157-158°C.
Example 13 3 4-pihydro-2,2-dimethyl-6-(2-methoxyphenytsulfonyl)= trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol
In analogy to Example 1 from Z-bromo-3,4-dihydro-2,2- i ~ dimethyl-6-(2-methoxyphenylsulfonyl)-2H-benzolblpyran-4- ha ol. White crystals of melting point: 196-198°C.
Example 14 3 4-pihydro-2,2-dimethyl-6-(2-methylphenylsulfonyl)= trans—4-(2-oxo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol
In analogy to Example 1. White crystals of melting point: . : 214-216°¢C.
Example 15 3 4-Dihydro-2,2-dimethyl-6-(2-chlorophenylsulfonyl)-
J 20 trans—b-(2-0xo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol
In analogy to Example 1. white crystals of melting point: 85-87°¢C
Example 16
Preparation of 3, 4-dihydro-2,2-dimethyl-6-phenylsulfonyl- trans-h-(2-0xo-1-pyrrolidinyl)-2H-benzolblpyran-3-ol (compound of Example 5S by process variant c)
A solution of 3_bromo-3,4-dihydro-2,2-dimethyl-6-phenyl- sulfonyl-2H-benzolblpyran-4-ol in ethanol is shaken under a pressure of 8 bar of NHz at 50° in an autoclave for 8 hours. The mixture is cooled and then evaporated to dryness and recrystallized from ethyl acetate. 4-Amino- 3,4-dihydro-2,2-dimethyl-6é-phenylsulfonyl-2H-benzolbl]- pyran-3-ol of melting point: 160-163°C is obtained and is immediately subjected to acylation with 4-chlorobutyr- yl chloride. For this purpose, the substance is dis- solved together with the acid chloride in CHpClp and stirred in a two-phase mixture with 2N sodium hydroxide solution at room temperature for 24 hours. The usual working up results in 4-(4-chlorobutyrylamino)-3,4-di- hydro-2,2-dimethyl-6-phenylsul fonyl-2H-benzolblpyran-4-ol of melting point 155-157°C. Cyclization to give the title compound is carried out by dissolving the substance ( J in tetrahydrofuran, addition of a stoichiometric amount of 80% NaH suspension in oil and stirring the mixture at room temperature for 24 hours. The final product is jdentical to the product obtained by process b). Melting point: 200-201°c. If 4-amino-3,4-dihydro-2,2-dimethyl- 6-phenylsul fonyl-2H-benzolblpyran-3-ol is subjected to racemate resolution, it is possible to obtain from its : 20 (+) enantiomer the pure (+) enantiomer from Example Sa with the data indicated there. : Example 17 3,4-Dihydro-2,2-dimethyl-6-phenylsulfoxy-trans-4-(2-oxo- ( 1-pyrrolidinyl)-2H-benzolblpyran-3-ol
In analogy to Example 1. Melting point: 211 - 212%
Pharmacological data a) Effect on respiratory tract disorders
Effect on histamine-induced bronchoconstriction in guinea-pigs
Method:
White guinea-pigs of both sexes and weighing between 450 and 550 g were anesthetized with 60 mg/kg pentobarbital i.p. After tracheotomy, they were ventilated with a
Starling pump (from Braun, Melsungen). The tidal volume was selected for generous ventilation of the Lungs. The ventilation pressure was adjusted to 80 mm H30 with the aid of a water column (Rosenthal and Dervinis). The breathing rate was 30 breaths/min. An excess of avail- able respiratory air can pass through a bypass in the inhalation tube to a washbottle which is designed as a water pressure-relief valve. When air is btown by the
Starling pump through the inhalation tube into the lungs they are inflated until the pressure in the system has reached the value set by the height of the water column [ | (80 mm Hp0). The continuing inflow of air flows through
Tr the pressure-relief valve into the washbottle. This excess air which escapes into the bottle after the set pressure has been exceeded is measured with the aid of a piston recorder and is taken as a measure of the change in the airway resistance. Measurement was carried out in a manner slightly modified from the original Konzett-
Rossler method, in that the piston recorder was replaced by a Fleisch dynamic pressure tube (type 0000). The difference in pressure which occurred was detected with a
Statham PM 97 TC differential pressure transducer. A
Hel lige multichannel pen recorder was used to record the ( 25 measurements. ) .
The test substances are administered as aerosol with the aid of an ultrasonic atomizer (Monaghan M 650). The atomizer chamber is interpolated in the inhalation tube } of the ventilation pump and allows the animals to inhale the aerosol for 1 min. The volume to be atomized is 0.02 ml/min.
Used for atomization is a physiological saline solution to which the substance to be tested is added in the form of a solution in propanediol.
It is ensured, in 3 control experiment, that the solvent propanediol/physiological satine solution has no action itself.
Bronchoconstriction is induced by doses of histamine di- hydrochloride (6 - 12 ug/kg i.v.). Injection is through a catheter introduced into the jugular vein. The dose is selected so that a respiratory "overflow" of 60% of the offered tidal volume occurs during the histamine- induced bronchoconstriction. The histamine doses are given at intervals of 5 minutes. After at least 3 well- reproduced bronchoconstrictions, the test substances are administered as aerosol for 1 min and, after an action { ) time of 2 min, the bronchoconstriction is induced anew and repeated at intervals of 5 minutes.
The degree of inhibition of the histamine-induced broncho- constriction after pretreatment with the test substance
Co : is regarded as a measure of the bronchodilator activity oo and is reported as % change from the control.
ALL results are subjected to Linear regression, and the
IDgg is determined.
Results: ( % inhibition of histamine-indu.ed br ~nchoconstriction
Compound Dose n % inhibition
Example 5a 1 ::g/kg 6 14 + 4 (+)-3,4-dihydro-2,2- 3 ug/kg 6 35 + 4 dimethyl-6é-phenyl- 10 ug/kg 6 or 7 sulfonyl-trans-4- (2-oxo0o-1-pyrrolidinyl)- 2H-benzolblpyran-3-ot
IDgg: 4.39 ug/kg —
b) Efferent urinary passages
Effect on the KCl-induced rhythmic contractions of the guinea-pig ureter in vitro
Method:
Male guinea-pigs were sacrificed by a blow to the back of the neck and exsanguination from the carotids. The two ureters were immediately removed, avoiding the region near the renal pelvis because of the pacemaker activity present there. Pieces 2 cm long were first freed of connective tissue in a petri dish containing Tyrode solu- my tion and then suspended in a 25 mL organ bath (from Rhema
No’ Labortechnik, Hofheim), in each case with a tension of 4.9 mN (= 0.5 p). The organ bath contained Tyrode solu- tion of the following composition (mmol/l): NaCl 137,
KCl 2.68, MgSO, 1.05, caClp 1.8, NaHaPO, 0.41, Co
NaHCOz 11.9, glucose 5.55, which was maintained at 37°C and through which carbogen (95% 0p, 5% C0p) was bubbled.
The contractions were measured isometrically using Gould/
Statham UC2 pickups. After an equilibration time of at least 15 minutes, KCL was added to the organ bath to reach a concentration of 4 x 10"2 mol/l. The agonist
Fo was left in the bath for 2 minutes, during which phasic contractions occurred without bringing about any note- worthy increase in the basic line tension.
Rinsing was then carried out for 1 minute, the rhythmic contractions ceasing immediately. After a second run with addition of agonist and the rinsing procedure, the test substance (benzopyran derivative) was added to the organ bath (in the form of a solution in 0.1 mL of ethanol; the final concentration was 10°" mol/L in all cases) and was allowed to act for one minute before KCl was added. The subsequent rinsing procedure was followed by two final additions of agonist/rinsing procedures.
The following parameters were determined in each of the two-minute periods during which KCl acted: 1. mean force of contraction, 2. frequency of contractions and 3. pro- duct of mean force and frequency of contractions.
The criteria for exclusion were mean forces of contrac- tion below 4 mN or frequencies of below 2/min in more than one of the four periods in which only the agonist
KCL was present in the bath. Evaluation was of the per- centage inhibition with the test substance compared with the mean value from the two initial runs.
C) Besides the arithmetic mean (x), the standard error of the mean (SEM) was calculated.
Results: n = number of ureters
Mean force Frequency v k . v n
Compound of con- (2) (%) traction
J k (2) 3,4-Dihydro-2,2- 68 + 11 , 67 + 14 85 + 7 4 / dimethyl-6-(2-chloro- phenylsulfonyl)- trans-4-(2-oxo-1- pyrrolidinyl)-2H- benzolblpyran-3-ol
Example 15 oo
Reference: R. Schiantarelli and W. Murmann, Arznei- mittel-Forschung/Drug Research 30, 1102 - 1109 (1980)
Claims (9)
1. A method for the treatment of obstructive functional disorders of the lungs in a patient, which comprises administering an effective amount of a compound of Formula I N ( C=0 4 , Ar-S0 OH n Ye 2 43 O (1) 1 3 JA 2 RZ RW 7 ~0 3 R in which : gl represents H, OH, (Cy-Cg)-alkoxy, (C3-Cz)- Lo . . 4,5 . :! 5 . . alkyl or NR®RY, where k* and R® are identical 14 or different and represent H, (Cy-Coialkyl or (Cy-Cg)-alkyleoarboayl, R= and R3 are identical or different and represent alkyl having 1-4 carbon atoms, Ar represents phenyl which ig unsubstituted or substituted by 1 to 3 identical or different radicals selected from (Cq1-Cop)-alkyl, (Cq1-Co)- : alkoxy, halogen. trifluoromethyl, CN, NO,, CO- (C{-Cop)-alkyl BOL (Cy -Cn)-alkyl with m = 1 or 2, n represents 1 or 2, {" X represents a chain (CHo) which oan be interrupted by & heteroatom #@, S or NRE, where &® denotes H or (Cy-Cy)-alkyl, and r represents 12 the nambers 2, 3, 4 or 5.
2. A pharmaceutical product for the treatment of obstructive functional disorders. of the . ur x] 0. h. spr AN . er . NER TE es Lae od So a ot . - : : lunge which comprises a compound as defined in Co claim 1 and a pharmaceutically acceptable 0 16 carrier.
3. The method as olaimed in claim 1, in which X denotes (CHn) po with r = 3 or 4.
4. The method as claimed in claim 1, wherein Ar represents phenyl which is unsubstituted or substituted ag in claim 1, and X denotes (CHp),. With r = 3 or 4.
5. The method as claimed in claim 1, wherein rl denotes hydrogen, RZ and RS represent (Cy1-Cr)-alkyl, Ar denotes phenyl which is unsubstituted op substituted once by (C1-Co)-alkoxy or halogen, ' n denotes 2, and X denoteg (CHp),. with r = 3 or 4g. 12
6. The method ag claimed in olain 1, wherein Lo . SRL = ~v~R! ‘dénstes hydrogen, RZ and RS represent (Cy-Co)-alkyl, X denotes (CHp) 4, 156 Ar denoteg Cel, Cl and n denotes 2,
7. The method as claimed in claim 1, wherein rl denotes hydrogen, RZ and R3 represent (C1-Co)-alkyl,
i . Ar denotes rhieny] , n denotes 2, and X dencteg (CHy) 5.
8. The method as claimed in claim 1, wherein the compound used is 3,4-dihydro-%, 2-dimethy]l- 6-(Z-chlorophenylsulfonyl)-trans-4-(2-oxo-1. Pyrrolidinyl)-2H-benzolblpyran-3-o] QU"
9. The method as claimed in claim 1, Wherein the compound used is 3,4-dihydro-2, 2-dimethy] - 19 6-phenylsulfonyl trans-4-(2-oxo-1-~ Lo ; as vo tee PYErOlidingl) -2H-benzo[blpyran-3-o1 i I - A3 -
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3824446A DE3824446A1 (en) | 1988-07-19 | 1988-07-19 | USE OF SUBSTITUTED 3,4-DIHYDRO-2H-BENZOPYRANE AS A MEDICINE AGAINST OBSTRUCTIVE FUNCTIONAL DISORDERS OF THE LUNG AND / OR DISORDERS OF THE LEADING URINE PATHS |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26696A true PH26696A (en) | 1992-09-15 |
Family
ID=6359009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH38951A PH26696A (en) | 1988-07-19 | 1989-07-17 | The use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP0351720B1 (en) |
JP (1) | JPH0273015A (en) |
KR (1) | KR900001367A (en) |
AT (1) | ATE110270T1 (en) |
AU (1) | AU621388B2 (en) |
CA (1) | CA1336891C (en) |
CZ (1) | CZ417091A3 (en) |
DE (2) | DE3824446A1 (en) |
DK (1) | DK171782B1 (en) |
ES (1) | ES2061816T3 (en) |
FI (1) | FI893460A (en) |
HU (1) | HU210149B (en) |
IE (1) | IE63872B1 (en) |
IL (1) | IL91015A (en) |
NZ (1) | NZ229961A (en) |
PH (1) | PH26696A (en) |
PT (1) | PT91197B (en) |
ZA (1) | ZA895459B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW244350B (en) * | 1991-12-14 | 1995-04-01 | Hoechst Ag | |
TW316850B (en) * | 1992-02-28 | 1997-10-01 | Takeda Pharm Industry Co Ltd | |
HUT72741A (en) * | 1992-12-19 | 1996-05-28 | Alkaloida Vegyeszeti Gyar | Method for producing benzopyrane derivatives and pharmaceutical compositions containing them |
GB9316111D0 (en) * | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Benzopyrans |
EP1244426A4 (en) * | 1999-12-23 | 2004-10-06 | Robert E Coifman | Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer |
KR100475147B1 (en) * | 2002-09-09 | 2005-03-10 | 정의상 | Remove noxious gas deodorant composite of alumina dust |
MXPA05004668A (en) | 2002-11-12 | 2005-06-08 | Warner Lambert Co | Method of stimulating hair growth using benzopyrans. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0107423B1 (en) * | 1982-10-19 | 1986-07-23 | Beecham Group Plc | Novel chromans and chromenes |
GB8419515D0 (en) * | 1984-07-31 | 1984-09-05 | Beecham Group Plc | Treatment |
GB8513369D0 (en) * | 1985-05-28 | 1985-07-03 | Beecham Group Plc | Treatment |
DE3881714D1 (en) * | 1987-02-04 | 1993-07-22 | Hoechst Ag | ALKYL-SUBSTITUTED N-BENZOPYRANYLLACTAME, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS. |
DE3703227A1 (en) * | 1987-02-04 | 1988-08-18 | Hoechst Ag | SUBSTITUTED 3,4-DIHYDRO-2H-BENZOPYRANES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS |
-
1988
- 1988-07-19 DE DE3824446A patent/DE3824446A1/en not_active Withdrawn
-
1989
- 1989-07-14 ES ES89112897T patent/ES2061816T3/en not_active Expired - Lifetime
- 1989-07-14 AT AT89112897T patent/ATE110270T1/en not_active IP Right Cessation
- 1989-07-14 EP EP89112897A patent/EP0351720B1/en not_active Expired - Lifetime
- 1989-07-14 DE DE58908228T patent/DE58908228D1/en not_active Expired - Fee Related
- 1989-07-17 PH PH38951A patent/PH26696A/en unknown
- 1989-07-17 NZ NZ229961A patent/NZ229961A/en unknown
- 1989-07-17 HU HU893591A patent/HU210149B/en not_active IP Right Cessation
- 1989-07-17 FI FI893460A patent/FI893460A/en not_active IP Right Cessation
- 1989-07-17 EP EP93105146A patent/EP0560399A1/en not_active Withdrawn
- 1989-07-18 KR KR1019890010129A patent/KR900001367A/en not_active Application Discontinuation
- 1989-07-18 PT PT91197A patent/PT91197B/en not_active IP Right Cessation
- 1989-07-18 AU AU38189/89A patent/AU621388B2/en not_active Ceased
- 1989-07-18 CA CA000605990A patent/CA1336891C/en not_active Expired - Fee Related
- 1989-07-18 JP JP1183848A patent/JPH0273015A/en active Pending
- 1989-07-18 IE IE232389A patent/IE63872B1/en not_active IP Right Cessation
- 1989-07-18 ZA ZA895459A patent/ZA895459B/en unknown
- 1989-07-18 DK DK355489A patent/DK171782B1/en not_active IP Right Cessation
- 1989-07-18 IL IL9101589A patent/IL91015A/en not_active IP Right Cessation
-
1991
- 1991-12-30 CZ CS914170A patent/CZ417091A3/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU621388B2 (en) | 1992-03-12 |
DK355489D0 (en) | 1989-07-18 |
DK171782B1 (en) | 1997-05-26 |
PT91197A (en) | 1990-02-08 |
FI893460A (en) | 1990-01-20 |
EP0560399A1 (en) | 1993-09-15 |
IE892323L (en) | 1990-01-19 |
DE3824446A1 (en) | 1990-01-25 |
NZ229961A (en) | 1991-11-26 |
IE63872B1 (en) | 1995-06-14 |
IL91015A (en) | 1994-11-28 |
DK355489A (en) | 1990-01-20 |
EP0351720A3 (en) | 1992-01-02 |
KR900001367A (en) | 1990-02-27 |
HUT55988A (en) | 1991-07-29 |
CZ417091A3 (en) | 1993-02-17 |
PT91197B (en) | 1995-07-18 |
DE58908228D1 (en) | 1994-09-29 |
FI893460A0 (en) | 1989-07-17 |
EP0351720B1 (en) | 1994-08-24 |
ZA895459B (en) | 1990-03-28 |
CA1336891C (en) | 1995-09-05 |
HU210149B (en) | 1995-02-28 |
ES2061816T3 (en) | 1994-12-16 |
EP0351720A2 (en) | 1990-01-24 |
AU3818989A (en) | 1990-01-25 |
JPH0273015A (en) | 1990-03-13 |
ATE110270T1 (en) | 1994-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5071871A (en) | Pharmaceutically useful benzo(β)pyranes and pyranopyridines | |
JP2793195B2 (en) | Benzothiazole derivative | |
US5096914A (en) | Novel benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds | |
PL141134B1 (en) | Method of manufacture of novel benzopyranes | |
JP2730421B2 (en) | 3,6-disubstituted pyridazine derivatives | |
JPS61293984A (en) | Active compound and its production and pharmaceutical composition containing the same | |
JP3048511B2 (en) | Novel N-pyridylcarboxamides and derivatives, methods for their production and pharmaceutical compositions containing them | |
AU604525B2 (en) | Substituted 3,4-dihydro-2h-benzopyrans, processes for their preparation, their use and pharmaceutical products based on these compounds | |
JPH06329540A (en) | Suppressor for arteriosclerotic intravascular membrane hyperplasia | |
JPH11508283A (en) | Benzofuryl derivatives and their uses | |
HUT54673A (en) | Process for producing benzopirane derivatives and pharmaceutical compositions containing them as active components | |
US5206252A (en) | Thiadiazolyl-amino derivatives of benzopyrans and indanes | |
US5250547A (en) | Benzopyran derivatives | |
DE69910799T2 (en) | AS INHIBITORS OF AICAR USEFUL LINKS | |
PH26696A (en) | The use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs | |
HU207729B (en) | Process for producing alkyl-substituted n-benzopyranyl-lactames and pharmaceutical compositions containing them | |
US5364878A (en) | Use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs | |
JPS62174062A (en) | 1,5-benzodiazepine derivative and production thereof | |
JPH02101074A (en) | 6-aloyl-substituted 3, 4-dihydro-2h-benzopyrane and its production | |
US5194442A (en) | 2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical products based on these compounds | |
CS207642B2 (en) | Method of making the substituted 2-cyclopropylchromones |